Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment.
Imatinib
chronic myeloid leukemia
morphology
platelets
scanning electron microscopy and transmission electron microscopy
Journal
Microscopy research and technique
ISSN: 1097-0029
Titre abrégé: Microsc Res Tech
Pays: United States
ID NLM: 9203012
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
15
12
2021
received:
06
09
2021
accepted:
19
01
2022
pubmed:
18
2
2022
medline:
26
5
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
Chronic myeloid leukemia (CML) is a myeloproliferative disease and the first line treatment is through the administration of Imatinib, a first generation tyrosine kinase inhibitor. Thrombocytosis and bleeding irregularities are common in CML, however, the morphological variations in CML patients' platelets are not well documented. In this study, ex vivo platelet morphology of control participants, as well as CML patients were assessed before and after Imatinib treatment. The topographical and structural morphology of platelets were determined via scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Qualitative data of SEM and TEM revealed that CML patient's platelets were prone to aggregation and coagulation at time of diagnosis; the samples that were not aggregated at time of diagnosis showed typical discoid shaped platelets, which was comparable to control participants' platelets. TEM results of CML patients' platelets at diagnosis showed that internal granular constituents including dense bodies were decreased in comparison to control participants. In all CML patients, platelets appeared activated after 6 months of treatment with Imatinib with membrane structure abnormalities and constituent variations. Research to date has primarily focused on the effects of CML on leukocyte populations, however, the results of the current study implicate the impact of CML pathogenesis on platelets, seemingly as a result of alterations in normal hematopoiesis. In addition, the impact of Imatinib treatment on platelet morphology was also established, indicating an increase in platelet activation. Recognizing and understanding the impact of CML disease progression on platelets is of importance to aid improved patient treatment. RESEARCH HIGHLIGHTS: In the study, results from SEM and TEM indicated that CML patient's platelets were prone to aggregation at time of diagnosis, and activation after Imatnib treatment. Platelet samples that did not aggregate had decreased internal granular constituents.
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2222-2233Subventions
Organisme : Cancer Association of South Africa
ID : AOV741
Organisme : Cancer Association of South Africa
ID : AOW228
Organisme : Medical Research Council of South Africa
ID : AOW110
Organisme : National Research Foundation
ID : N00375
Organisme : National Research Foundation
ID : N00591
Organisme : School of Medicine Research Committee of the Faculty of Health Sciences
ID : AOR984
Organisme : Struwig-Germeshuysen Research Trust
ID : AON074
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Breccia, M., & Alimena, G. (2014). Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs. Mediterranean Journal of Hematology and Infectious Diseases, 6(1), e2014003.
Buys, A. V., & Pretorius, E. (2012). Comparing different preparation methods to study human fibrin fibers and platelets using TEM. Microscopy Research and Technique, 75(6), 801-806.
Deb, S., Boknäs, N., Sjöström, C., Tharmakulanathan, A., Lotfi, K., & Ramström, S. (2020). Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications? Cancer Medicine, 9(1), 313-323.
Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., Mead, M., & Sundar, H. (2020). Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 18(10), 1385-1415.
Elaskalani, O., Berndt, M. C., Falasca, M., & Metharom, P. (2017). Targeting platelets for the treatment of cancer. Cancers, 9(7), 94.
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999). The biology of chronic myeloid leukemia. New England Journal of Medicine, 341(3), 164-172.
Goldman, J. M., & Melo, J. V. (2003). Chronic myeloid leukemia-Advances in biology and new approaches to treatment. New England Journal of Medicine, 349(15), 1451-1464.
Goldstein, J. I., Newbury, D. E., Michael, J. R., Ritchie, N. W., Scott, J. H. J., & Joy, D. C. (2017). Scanning electron microscopy and X-ray microanalysis. Springer.
Graves, D. T., Grotendorst, G. R., Antoniades, H. N., Schwartz, C. J., & Valente, A. J. (1989). Platelet-derived growth factor is not chemotactic for human peripheral blood monocytes. Experimental Cell Research, 180(2), 497-503.
Hehlmann, R., Hochhaus, A., & Baccarani, M. (2007). Chronic myeloid leukaemia. The Lancet, 370(9584), 342-350.
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., & Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984.
Hoffbrand, A. V., Higgs, D. R., Keeling, D. M., & Mehta, A. B. (2016). Postgraduate haematology. John Wiley & Sons.
Holinstat, M. (2017). Normal platelet function. Cancer and Metastasis Reviews, 36(2), 195-198.
Hurbain, I., & Sachse, M. (2011). The future is cold: Cryo-preparation methods for transmission electron microscopy of cells. Biology of the Cell, 103(9), 405-420.
Kikuchi, J. I., & Yasuhara, K. (John Wiley & Sons, Ltd.; 2012). Transmission electron microscopy (TEM). In Supramolecular chemistry: From molecules to nanomaterials, pp. 1-13. John Wiley & Sons, Ltd. https://doi.org/10.1002/9780470661345.smc022
Lakhotia, M., Pahadiya, H. R., Prajapati, G. R., Choudhary, A., & Gandhi, R. (2015). Spontaneous soft tissue haematomas - A rare presentation of Chronic Myeloid Leukemic (CML). Journal of Clinical and Diagnostic Research: JCDR, 9(7), OD03.
Latger-Cannard, V., Fenneteau, O., Salignac, S., Lecompte, T. P., & Schlegel, N. (2013). Platelet morphology analysis. In Haemostasis (pp. 207-225). Humana Press.
Li, J., Xia, Y., Bertino, A. M., Coburn, J. P., & Kuter, D. J. (2000). The mechanism of apoptosis in human platelets during storage. Transfusion, 40(11), 1320-1329.
Louw, V. J., Dreosti, L., Ruff, P., Patel, M., Willem, P., Jogessar, V., Moodley, D., Novitzky, N., & Schmidt, A. (2011). Recommendations for the management of adult chronic myeloid leukaemia in South Africa: Guideline. South African Medical Journal, 101(11), 840-846.
Mauro, M. J. (2006). Defining and managing imatinib resistance. ASH Education Program Book, 2006(1), 219-225.
Meikle, C. K., Kelly, C. A., Garg, P., Wuescher, L. M., Ali, R. A., & Worth, R. G. (2017). Cancer and thrombosis: The platelet perspective. Frontiers in Cell and Developmental Biology, 4, 147.
Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021). Chronic myeloid leukemia: A model disease of the past, present and future. Cell, 10(1), 117.
Ning, L., Hu, C., Lu, P., Que, Y., Zhu, X., & Li, D. (2020). Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: A population-based epidemiologic study. Experimental Hematology & Oncology, 9(1), 1-14.
Oda, A., Miyakawa, Y., Druker, B. J., Ishida, A., Ozaki, K., Ohashi, H., Wakui, M., Handa, M., Watanabe, K., Okamoto, S., & Ikeda, Y. (1996). Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
Oehler, V. G. (2020). First-generation vs second-generation tyrosine kinase inhibitors: Which is best at diagnosis of chronic phase chronic myeloid leukemia? Hematology 2014, the American Society of Hematology Education Program Book, 2020(1), 228-236.
Olsson, A. K., & Cedervall, J. (2018). The pro-inflammatory role of platelets in cancer. Platelets, 29(6), 569-573.
Ozgur Yurttas, N., & Eskazan, A. E. (2019). Tyrosine kinase inhibitor - Associated platelet dysfunction: Does this need to have a significant clinical impact? Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619866925.
Parise, L. V., Smyth, S. S., & Coller, B. S. (2001). Platelet morphology, biochemistry and function. Williams Hematology, 7, 1597-1645.
Pophali, P. A., & Patnaik, M. M. (2016). The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer Journal, 22(1), 40.
Pretorius, E. (2007). The role of platelet and fibrin ultrastructure in identifying disease patterns. Pathophysiology of Haemostasis and Thrombosis, 36(5), 251-258.
Pretorius, E. (2012). Ultrastructural changes in platelet membranes due to cigarette smoking. Ultrastructural Pathology, 36(4), 239-243.
Quintás-Cardama, A., Han, X., Kantarjian, H., & Cortes, J. (2009). Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood, The Journal of the American Society of Hematology, 114(2), 261-263.
Repsold, L., Pool, R., Karodia, M., Tintinger, G., Becker, P., & Joubert, A. M. (2021). Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib. Cell Biochemistry and Function, 39(4), 562-570.
Sawyers, C. L. (1999). Chronic myeloid leukemia. New England Journal of Medicine, 340(17), 1330-1340.
Sener, Y., Okay, M., Aydin, S., Buyukasik, Y., Akbiyik, F., & Dikmen, Z. G. (2019). TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response. Clinical and Applied Thrombosis/Hemostasis, 25, 1076029619858409.
Vernon-Parry, K. D. (2000). Scanning electron microscopy: An introduction. III-Vs Review, 13(4), 40-44.
White, J. G., & Gerrard, J. M. (1978). The ultrastructure of defective human platelets. Molecular and Cellular Biochemistry, 21(2), 109-128.
White, J. G., & Michelson, A. (2007). Platelet structure. Platelets, 2, 45-71.
Wojtukiewicz, M. Z., Sierko, E., Hempel, D., Tucker, S. C., & Honn, K. V. (2017). Platelets and cancer angiogenesis nexus. Cancer and Metastasis Reviews, 36(2), 249-262.